Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN ®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia

Journal of the Neurological Sciences

Volumn 308, Issue 1-2, 2011, Pages 103-109

  Comella, Cynthia L ^a   Jankovic, Joseph ^a   Truong, Daniel D ^a   Hanschmann, Angelika ^a   Grafe, Susanne ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Botulinum toxin type A; Cervical dystonia; IncobotulinumtoxinA; NT 201

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; APPENDICITIS; ARTICLE; ASTHMA; CERVICAL DYSTONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STIFFNESS; MUSCLE WEAKNESS; NECK PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; DEGLUTITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; PROSPECTIVE STUDIES; TORTICOLLIS; TREATMENT OUTCOME;

EID: 80051579448     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.05.041     Document Type: Article

References (17)

1. D.M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, and M. Hallett Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 19 2008 1699 1706
2. ® (incobotulinumtoxinA) for injection US Prescribing Information 2010
3. J. Frevert Xeomin is free from complexing proteins Toxicon 54 5 2009 697 701
4. H. Bigalke Properties of pharmaceutical products of botulinum neurotoxins J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer, Botulinum Toxin - Therapeutic Clinical Practice & Science 2008 Saunders Elsevier Philadelphia 389 395
5. J. Frevert Xeomin: an innovative new botulinum toxin type A Eur J Neurol 16 Suppl 2 Dec. 2009 11 13
6. P. Roggenkamper, W.H. Jost, K. Bihari, G. Comes, and S. Grafe Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm J Neural Transm 113 3 2006 303 312
7. R. Benecke, W.H. Jost, P. Kanovsky, E. Ruzicka, G. Comes, and S. Grafe A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 64 11 2005 1949 1951
8. E. Consky, A. Basinski, L. Belle, R. Ranawaya, and A.E. Lang The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (Abstract 1199P) Neurology 40 Suppl 1 1990
9. A. Brashear, M.F. Lew, D.D. Dykstra, C.L. Comella, S.A. Factor, and R.L. Rodnitzky Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 7 1999 1439 1446
10. M.F. Brin, M.F. Lew, C.H. Adler, C.L. Comella, S.A. Factor, and J. Jankovic Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 7 1999 1431 1438
11. D. Truong, D.D. Duane, J. Jankovic, C. Singer, L.C. Seeberger, and C.L. Comella Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study Mov Disord 20 7 2005 783 791
12. ® (onabotulinumtoxinA) for injection US Prescribing Information 2009
13. D. Truong, M. Lew, and O. Orlova Efficacy of Dysport (botulinum toxin type A) for the treatment of cervical dystonia: a multicenter, randomized, double blind, placebo-controlled phase III study Toxicon 51 2008 37
14. Merz Pharmaceuticals, GmbH Data on File, Frankfurt, Germany 2010
15. C.L. Comella, J. Jankovic, K.M. Shannon, J. Tsui, M. Swenson, and S. Leurgans Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia Neurology 65 9 2005 1423 1429
16. F. Chen, G.M. Kuziemko, P. Amersdorfer, C. Wong, J.D. Marks, and R.C. Stevens Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms Infect Immun 65 5 May 1997 1626 1630
17. Y. Fujinaga Interaction of botulinum toxin with the epithelial barrier J Biomed Biotechnol 2010 10.1155/2010/974943